Efficacy of pharmacotherapy for comorbid major depression and substance use disorders: A review

Current Psychiatry Reviews

Volumn 4, Issue 1, 2008, Pages 14-27

  Salloum, Ihsan M ^a   Jones, Yemisi Olagunju ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alcoholism; Cocaine dependence; Comorbidity of depression and addictive disorders; Dual diagnosis; Major depression; Opioid dependence; Pharmacotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; BICYCLIC ANTIDEPRESSANT AGENT; DESIPRAMINE; DISULFIRAM; FLUOXETINE; IMIPRAMINE; METHADONE; NALTREXONE; NEFAZODONE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; VILOXAZINE;

ALCOHOLICS ANONYMOUS; ALCOHOLISM; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; METHADONE TREATMENT; METHODOLOGY; MONOTHERAPY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SUBSTANCE ABUSE; VALIDITY;

EID: 41949131856     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340008783743785     Document Type: Review

References (52)

1. World Health Organization:The World Health Report 2001 - Mental Health:New Understanding, New hope. World Health Organization, 2001.
2. Regier DA, Farmer ME, Rae DS, Loeke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264(19): 2511-8.
3. Kessler RC, Crum RM, Warner LA, Nelson CB. Lifetime co-occurrence ofDSM-III-Ralcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54(4): 313-321.
4. Grant BF, Stinson FS, Dawson DA, Chou SP, Ruan WJ, Pickering RP. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States:results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61(4): 361-8.
5. Kessler RC, Chiu WT, Demler O, Walters EE:Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication [see comment]. Arch Gen Psychiatry 2005; 62(6): 617-27.
6. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS:Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51(1): 8-19.
7. Mezzich JE, Ahn CW, Fabrega HJr, Pilkonis PA.Patterns of psychiatric comorbidity in a large population presenting for care. In:Maser JD, Cloninger RC, Ed, Comorbidity of mood and anxiety disorders, vol xvii. Washington, DC,American Psychiatric Press, Inc, 1990; 189-204.
8. Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biometric Bull 1946; 2: 47-53.
9. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders:results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67(2): 247-57.
10. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders:results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61(8): 807-16.
11. Hasin DSP, Goodwin RDP, Stinson FSP, Grant BFPP. Epidemiology of Major Depressive Disorder:Results From the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62(10): 1097-1106.
12. Thase M, Salloum I, Cornelius J. Comorbid alcoholism and depression: treatment issues. J Clin Psychiatry 2001; 62 Suppl 20: 32-41.
13. Liskow, Barry, Mayfield, Demmie, Thiele, Jeffrey. Alcohol and affective disorder:Assessment and treatment. J Clin Psychiatry 1982; 43(4): 144-147.
14. Schuckit MA. The relationship between alcohol problems, substance abuse, and psychiatric syndromes. In:Widiger AT, Frances JA, Pincus HA, First BM, Ross R, Davis W Ed. DSM-IV Sourcebook, vol 1. Washington, DC, American Psychiatric Association, 1994; 45-66.
15. Crowe DB, Rosse RB, Sheridan MJ, Deutsch SI. Substance use diagnoses and discharge patterns among psychiatric inpatients. Hosp Community Psychiatr 1991; 42(4): 403-5.
16. Hesselbrock MN, Tennen H, Hesselbrock V, Workman-Daniels K, Meyer RE:Assessment of depression in alcoholics:further considerations-reply to Hagan and Schauer. J Consult Clin Psychol 1985; 53(1): 67-9.
17. Murphy GE, Wetzel RD, Robins E, McEvoy L. Multiple risk factors predict suicide in alcoholism. Arch Gen Psychiatry 1992; 49(6): 459-63.
18. Anton RF, O'Malley SS, Ciraulo DA, et. al. Combined pharma-cotherapies and behavioral interventions for alcohol dependence: the COMBINE study:a randomized controlled trial. JAMA 2006; 295(17): 2003-17.
19. Pettinati H, Volpicelli J, Luck G, Kranzler H, Rukstalis M, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21(2): 143-53.
20. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N:Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152(3): 391-7.
21. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, Hasin D, Keller M. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006; 26(1): 13-20.
22. Gual A, Balcells M, Torres M, Madrigal M, Diez T, Serrano L. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder:a randomized controlled trial. Alcohol Alcohol 2003; 38(6): 619-25.
23. Moak DH, Anton RF, Latham PK, Voronin KE, Waid RL, Durazo-Arvizu R. Sertraline and cognitive behavioral therapy for depressed alcoholics:results of a placebo-controlled trial. J Clin Psychopharmacol 2003; 23(6): 553-62.
24. Roy, A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry. 1998; 44(7), 633-637.
25. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius M, Perel JM, Thase ME, Black AM. Fluoxetine in Depressed Alcoholics:A Double-blind, Placebo-Controlled Trial. Arh Gen Psychiatry 1997; 54(8): 700-705.
26. Cornelius JR, Salloum IM, Haskett RF, Daley DC, Cornelius MD, Thase ME, Perel JM. Fluoxetine versus placebo in depressed alcoholics: a 1-year follow-up study. Addict Behav. 2000; 25(2): 307-10.
27. Garcia-Portilla MP, Bascaran MT, Saiz PA, Mateos M, Gonzalez-Quiros M, Perez P, Avila JJ, Torres MA, Bombin R, Caso C, Marin R, Prieto R, Bobes J. [Effectiveness of venlafaxine in the treatment of alcohol dependence with comorbid depression]. [Spanish]. Actas Espanolas de Psiquiatria 2005; 33(l): 41-5.
28. Hernandez-Avila CA, Modesto-Lowe V, Feinn R, Kranzler HR. Nefazodone treatment of comorbid alcohol deperdence and major depression. Alcohol Clin Exp Res 2004; 28(3): 433-40.
29. Roy-Byrne PP, Pages KP, Russo JE, Jaffe C, Blume AW, Kingsley E, Cowley DS, Ries RK. Nefazodone treatment of major depression in aldohol-dependent patients:a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000; 20(2): 129-36.
30. McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM. Imipramine treatment of alcoholics with primary depression:a placebo-controlled clinical trial. Arch Gen Psychiatry 1996; 53(3): 232-40.
31. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275(10): 761-7.
32. Nunes EV, McGrath PJ, Quitkin FM, Stewart JP, Harrison W, Tricamo E, Ocepek-Welikson K. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry 1993; 150(6): 960-5.
33. Altamura AC, Mauri MC, Girardi T, Panetta B. Alcoholism and depression:a placebo controlled study with viloxazine. Int J Clin Pharmacol Res 1990; 10(5): 293-8.
34. Pinder RM, Brogden RN, Speight TM, Avery GS. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977; 13(3): 161-218.
35. Oslin DW. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry 2005; 13(6): 491-500.
36. Petrakis I, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 2005; 57(10): 1128-37.
37. Salloum IM, Cornelius JR, Thase ME, Daley DC, Kirisci L, Spotts C. Naltrexone utility in depressed alcoholics. Psychopharmacol Bull 1998; 34(l): 111-5.
38. Borup C, Unden M. Combined fluoxetine and disulfiram treatment of alcoholism with comorbid affective disorders:A naturalistic outcome study, including quality of life measurements. Eur Psychiatry 1994; 9(2): 83-89.
39. Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 2001; 63(3): 207-14.
40. Ciraulo DA, Knapp C, Rotrosen J, Sarid-Segal O,, Ciraulo AM, LoCastro J, Greenblatt DJ, Leiderman D. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction 2005; 1: 23-31.
41. McDowell D, Nunes EV, Seracini AM, Rothenberg J, Vosburg SK, Ma GJ, Petkova E. Desipramine treatment of cocaine-dependent patients with depression:a placebo-controlled trial. Drug Alcohol Depend 2005: 80(2): 209-21.
42. Nunes EV, McGrath PJ, Quitkin FM, Ocepek-Welikson K, Stewart JW, Koenig T, Wager S, Klein DF. Imipramine treatment of cocaine abuse:possible boundaries of efficacy. Drug Alcohol Depend 1995; 39(3): 185-95.
43. Carpenter KM, Brooks AC, Vosburg SK, Nunes EV. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients:a controlled clinical trial. Drug Alcohol Depend 2004; 74(2): 123-34.
44. Dean AJ, Bell J, Mascord DJ, Parker G, Christie MJ. A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord 2002; 72(l): 85-90.
45. Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend 1998; 50(3): 221-6.
46. Nunes EV, Quitkin FM, Donovan SJ, Deliyannides D, Ocepek-Welikson K, Koenig T, Brady R, McGrath PJ, Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry 1998; 55(2): 153-60.
47. Kleber HD, Weissman MM, Rounsaville BJ, Wilber CH, Prusoff BA, Riordan CE. Imipramine as treatment for depression in addicts. Arch Gen Psychiatry 1983; 40(6): 649-53.
48. Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21(2): 143-53.
49. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A, Perel JM, Thase ME. Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacol Bull 1997; 33(l): 165-70.
50. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence:a meta-analysis. JAMA 2004; 291(15): 1887-96.
51. Pettinati HM. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry 2004; 56(10): 785-792.
52. Hesin D, Hatzenbuehler ML, Keyes K, Ogburn E. Substance use disorders:Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10) Addiction 2006; 101(sl): 59-75.